De­spite 'lack­lus­ter' 2022, PwC re­mains 'bull­ish' on phar­ma M&A in 2023

While 2022 was shap­ing up to be a busy year for M&A, PwC record­ed an over­all “lack­lus­ter” amount of ac­tiv­i­ty, with both deal size and vol­ume down from last year. How­ev­er, the ac­count­ing firm pre­dicts a 2023 re­bound.

In its lat­est deals out­look re­port, PwC pre­dict­ed a more ac­tive 2023, with “M&A to more close­ly re­sem­ble pri­or years with a to­tal deal val­ue in the $225 bil­lion to $275 bil­lion range across all sub­sec­tors.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.